-
公开(公告)号：US20240239789A1
公开(公告)日：2024-07-18
申请号：US18400204
申请日：2023-12-29
Applicant: Ceruvia Lifesciences LLC
Inventor： Gillian Moore , Julian S. Northern
IPC: C07D457/06 , A61K31/48 , C07C57/15 , C07C309/04 , C07C309/29
CPC classification number: C07D457/06 , A61K31/48 , C07C57/15 , C07C309/04 , C07C309/29 , C07B2200/13
Abstract: The present disclosure relates to salts of 2-bromolysergic acid diethylamide (2-Br-LSD), pharmaceutical compositions thereof, and methods of preparing and using the 2-Br-LSD salts.
-
2.发明公开
公开(公告)号：US20240101564A1
公开(公告)日：2024-03-28
申请号：US18517894
申请日：2023-11-22
Applicant: BeiGene Switzerland GmbH
Inventor： Jing LI , Xiaosong YU , Xiaopeng CAI , Zhiwei WANG
IPC: C07D487/04 , C07C53/128 , C07C57/15 , C07C59/255 , C07C65/05 , C07D213/80
CPC classification number: C07D487/04 , C07C53/128 , C07C57/15 , C07C59/255 , C07C65/05 , C07D213/80 , C07B2200/13
Abstract: The present invention relates to salts of a PI3Kdelta inhibitor (referred to as “Compound A” hereinafter), preferably fumarate, and the crystalline forms thereof. The present invention also relates to the process of preparation and uses of the salts and crystalline forms of Compound A.
-
公开(公告)号：US11795150B2
公开(公告)日：2023-10-24
申请号：US16535453
申请日：2019-08-08
Applicant: Philera New Zealand Limited
Inventor： Marco Jonas , Irene Vaulont , Antonio Soi , Gunther Schmidt
IPC: C07D233/02 , C07C55/10 , C07C57/145 , C07C57/15 , C07C209/48 , C07C209/62 , C07C211/10 , C07C211/14 , C07D233/26 , C07C211/13 , C07C209/76 , C07C255/30
CPC classification number: C07D233/02 , C07C55/10 , C07C57/145 , C07C57/15 , C07C209/48 , C07C209/62 , C07C209/76 , C07C211/10 , C07C211/13 , C07C211/14 , C07C255/30 , C07D233/26 , C07B2200/13 , C07C209/48 , C07C211/14 , C07C209/62 , C07C211/14 , C07C209/48 , C07C211/10 , C07C209/62 , C07C211/10
Abstract: Methods and intermediates for synthesizing triethylenetetramine and salts thereof, as well as novel triethylenetetramine salts and their crystal structure, and triethylenetetramine salts of high purity.
-
公开(公告)号：US20190040077A1
公开(公告)日：2019-02-07
申请号：US16073705
申请日：2017-01-27
Inventor： Venumadhav Janganati , Peter Crooks , Jessica Ponder , Craig Jordan
IPC: C07D493/04 , A61P35/00 , C07C57/15
CPC classification number: C07D493/04 , A61K31/4192 , A61P35/00 , C07C57/15
Abstract: The present disclosure relates to triazole derivatives of melampomagnolide B, their synthesis, and their use as anti-cancer compounds.
-
公开(公告)号：US10039761B2
公开(公告)日：2018-08-07
申请号：US15130266
申请日：2016-04-15
Applicant: Vertex Pharmaceuticals Incorporated
Inventor： Kwame Wiredu Nti-Addae , Simon Adam O'Neil , Yuegang Zhang , Michael Waldo , Praveen Mudunuri , Bin Song , John Gregg Van Alsten , Mark Strohmeier , Kathy Stavropoulos , Irina Nikolaevna Kadiyala , Mettachit Navamal
IPC: A61K31/33 , A61K31/506 , C07D401/14 , A61K31/337 , A61K31/5025 , A61K31/513 , A61K31/517 , A61K31/555 , A61K31/704 , A61K31/7048 , A61K33/24 , A61K38/14 , A61K39/395 , A61K45/06 , C07B59/00 , C07C55/10 , C07C55/14 , C07C57/145 , C07C57/15 , C07C59/265 , C07C63/08 , C07K16/28 , A61N5/10
CPC classification number: A61K31/506 , A61K31/337 , A61K31/5025 , A61K31/513 , A61K31/517 , A61K31/555 , A61K31/704 , A61K31/7048 , A61K33/24 , A61K38/14 , A61K39/39558 , A61K45/06 , A61N2005/1098 , A61P35/00 , C07B59/002 , C07B2200/05 , C07B2200/13 , C07C55/10 , C07C55/14 , C07C57/145 , C07C57/15 , C07C59/265 , C07C63/08 , C07D401/14 , C07K16/2863 , C07K2317/24
Abstract: The present invention relates to compositions and co-crystals each comprising a compound of formula I having the structure: wherein each of R1 and R2 is H or 2H and a co-crystal former selected from adipic acid, citric acid, fumaric acid, maleic acid, succinic acid, or benzoic acid. Also within the scope of this invention are methods of making and using the same.
-
公开(公告)号：US09877942B1
公开(公告)日：2018-01-30
申请号：US15430750
申请日：2017-02-13
Applicant: SyneuRx International (Taiwan) Corp.
Inventor： Guochuan Emil Tsai , Ching-Cheng Wang , Tien-Lan Hsieh
IPC: A61K31/198 , A61K47/12 , C07C229/12 , C07C59/255 , C07C57/15 , C07D307/62
CPC classification number: A61K31/198 , A61K47/12 , C07B2200/13 , C07C57/15 , C07C59/255 , C07C229/12 , C07D307/62
Abstract: The present disclosure provides co-crystals of a substituted glycine compound and a co-former compound of Formula (I): compositions comprising such, and uses thereof in treating and/or reducing the risk for a neuropsychiatric disorder (e.g., schizophrenia, psychotic disorders, depressive disorders, suicidal ideation and/or behavior, obsessive compulsive disorder or Alzheimer's disease). Also provided herein are methods for preparing the co-crystals.
-
公开(公告)号：US09845284B1
公开(公告)日：2017-12-19
申请号：US15368618
申请日：2016-12-04
IPC: C07C229/00 , C07C227/18 , C07C51/41
CPC classification number: C07C227/18 , C07C51/418 , C07C57/15 , C07C55/10 , C07C229/24
Abstract: A method of obtaining a complex acidic salt of a divalent metal and a dicarboxylic acid includes heating water in a reactor; adding a dicarboxylic acid to the heated water; stirring the water to dissolve the dicarboxylic acid in the heated water to produce a solution or a suspension of the dicarboxylic acid in the heated water; adding MeO to the solution or the suspension, where Me is a divalent metal; continuing the stirring of the solution or suspension until formation of the complex acidic salt Me(AcH)2.nH2O begins, where Ac is an anion of the dicarboxylic acid, and n=0-8; cooling the complex acidic salt to below a temperature of crystallization; sedimenting the complex acidic salt; filtering the complex acidic salt to remove water from the complex acidic salt; and drying the complex acidic salt.
-
公开(公告)号：US09827217B2
公开(公告)日：2017-11-28
申请号：US15281329
申请日：2016-09-30
Applicant: Rgenix, Inc.
Inventor： Eduardo J. Martinez , Andreas G. Grill , Aniruddh Singh , Padmini Kavuru
IPC: A61K31/197 , A61K9/00 , A61K47/12
CPC classification number: A61K31/197 , A61K9/0019 , A61K47/12 , C07C57/15 , C07C279/14
Abstract: The present invention relates to new pharmaceutical salts of β-GPA which exhibit improved physical properties. In particular, the invention relates to salts of β-GPA with improved flow properties (e.g., improved Carr's index and/or Hausner ratio) such as fumarate salts, succinate salts, and oxalate salts. The invention also relates to pharmaceutical compositions including a pharmaceutically effective amount of one or more salts of β-GPA, as well as methods of treating cancer including administration of a formulation including a β-GPA salt of the invention to a subject in need thereof.
-
公开(公告)号：US20170275264A1
公开(公告)日：2017-09-28
申请号：US15452430
申请日：2017-03-07
Applicant: Yves AUBERSON , Mark Gary BOCK , Dario BRAGA , Marco CURZI , Stephanie Kay DODD , Stefano Luca GIAFFREDA , Haiyang JIANG , Piotr KARPINSKI , Thomas J. TROXLER , Tie-Lin WANG , Xiaoyang WANG , Xuechun ZHANG
Inventor： Yves AUBERSON , Mark Gary BOCK , Dario BRAGA , Marco CURZI , Stephanie Kay DODD , Stefano Luca GIAFFREDA , Haiyang JIANG , Piotr KARPINSKI , Thomas J. TROXLER , Tie-Lin WANG , Xiaoyang WANG , Xuechun ZHANG
IPC: C07D401/04 , C07D403/04 , C07C57/15 , C07C59/265 , A61K31/496 , A61K31/501
CPC classification number: C07D401/04 , A61K31/496 , A61K31/501 , C07B2200/13 , C07C57/15 , C07C59/265 , C07D403/04
Abstract: The invention relates to compound of the formula I or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.
-
公开(公告)号：US09757416B2
公开(公告)日：2017-09-12
申请号：US14701933
申请日：2015-05-01
Applicant: Panion & BF Biotech Inc.
Inventor： Keith Chan , Winston Town , David W. K. Kwok , Nikolay Mintchev Stoynov
IPC: A61K33/26 , A61K31/295 , C07C51/41 , C07C59/265
CPC classification number: A61K33/26 , A61K31/295 , C07C51/412 , C07C51/418 , C07C59/265 , C07C55/10 , C07C59/255 , C07C53/08 , C07C59/245 , C07C57/15
Abstract: The present invention discloses pharmaceutical-grade ferric organic compounds, including ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. A manufacturing and quality control process for making a pharmaceutical-grade ferric citrate that consistently complies with the established Manufacture Release Specification is also disclosed. The pharmaceutical-grade ferric organic compounds are suitable for treating disorders characterized by elevated serum phosphate levels.
